Last reviewed · How we verify
Gefitinib and capecitabine
At a glance
| Generic name | Gefitinib and capecitabine |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer (PHASE1, PHASE2)
- Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors (PHASE1)
- IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gefitinib and capecitabine CI brief — competitive landscape report
- Gefitinib and capecitabine updates RSS · CI watch RSS
- AstraZeneca portfolio CI